<DOC>
	<DOCNO>NCT00690053</DOCNO>
	<brief_summary>Non invasive imaging hypoxia aid PET-scans could help select patient hypoxic tumour could treat specific anti-hypoxic treatment bio-reductive drug hypoxic radio-sensitizers . Several 2-nitroimidazoles compound test , HX-4 , belong , label Fluor-18 already use patient . However , bad image quality unpredictable kinetics limit use . In extensive pre-clinical model , combination HX-4 label Fluor-18 promise non-toxic new probe determine hypoxia .</brief_summary>
	<brief_title>Non-Invasive Imaging 18FHX4 With Positron-Emission-Tomography ( PET )</brief_title>
	<detailed_description>To determine toxicity hypoxia PET-tracer [ 18F ] -HX4 cancer patient two dose-steps : - Step 1 ( 3-6 patient ) : single dose maximum 6 mCi ( 222 MBq ) dose [ 18F ] HX4 ( contain maximum 15 μg HX-4 ) via bolus IV injection . - Step 2 ( 3-6 patient ) : single dose maximum 12 mCi ( 444 MBq ) dose [ 18F ] HX4 ( contain maximum 27 μg HX-4 ) via bolus IV injection .</detailed_description>
	<criteria>Histological cytological confirm solid tumour , primary secondary stage IV and/ tumour curative treatment option . Normal white blood cell count neutrophil Normal platelet count No anaemia require blood transfusion erythropoietin Adequate hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) institution ; ALT , AST , alkaline phosphatase ≤ 2.5 x ULN institution ) . Calculated Creatinin clearance least 60 ml/min No administration Fluor18 previous 24 hour Capable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Toxicity</keyword>
	<keyword>PET</keyword>
	<keyword>HX-4</keyword>
	<keyword>cancer</keyword>
</DOC>